These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10184934)

  • 21. Economic benefit analysis of primary prevention with pravastatin. Assumptions are methodologically flawed.
    Freemantle N; Mason J
    BMJ; 1998 Apr; 316(7139):1241-2. PubMed ID: 9583930
    [No Abstract]   [Full Text] [Related]  

  • 22. [Decreasing LDL level moderately or drastically. Is differential therapy with statins available? (interview by Dirk Einecke)].
    März W
    MMW Fortschr Med; 2004 Jul; 146(27-28):53. PubMed ID: 15526673
    [No Abstract]   [Full Text] [Related]  

  • 23. Pravastatin and coronary heart disease.
    Assmann G; Schulte H; Cullen P
    Circulation; 1998 Dec 22-29; 98(25):2933-4. PubMed ID: 9860800
    [No Abstract]   [Full Text] [Related]  

  • 24. Improved survival with statin therapy.
    Clem JR
    S D J Med; 1996 Aug; 49(8):273-4. PubMed ID: 8803474
    [No Abstract]   [Full Text] [Related]  

  • 25. [For coronary disease patients is certain: the lower the LDL the better].
    MMW Fortschr Med; 2006 Jun; 148(24):6. PubMed ID: 16850797
    [No Abstract]   [Full Text] [Related]  

  • 26. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.
    Caro J; Klittich W; McGuire A; Ford I; Norrie J; Pettitt D; McMurray J; Shepherd J
    BMJ; 1997 Dec; 315(7122):1577-82. PubMed ID: 9437275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statin therapy for prevention of coronary artery disease with average cholesterol levels.
    Gambhir DS
    Indian Heart J; 1999; 51(1):19-20, 105. PubMed ID: 10327772
    [No Abstract]   [Full Text] [Related]  

  • 28. [Statin treatment in type 2 diabetes. Is it a must today?].
    Faust M
    MMW Fortschr Med; 2003 Feb; 145(9):35-6. PubMed ID: 12666527
    [No Abstract]   [Full Text] [Related]  

  • 29. [Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
    Sudhop T; von Bergmann K
    MMW Fortschr Med; 2003 May; 145(21):19. PubMed ID: 12845862
    [No Abstract]   [Full Text] [Related]  

  • 30. Results of recent trials on the progression of coronary artery disease and recurrent ischemic events: implications for interventional cardiology.
    Pitt B
    J Interv Cardiol; 1994 Dec; 7(6):515-8. PubMed ID: 10155198
    [No Abstract]   [Full Text] [Related]  

  • 31. Economic benefit analysis of primary prevention with pravastatin. Modelling economic benefits after such long term treatment is inappropriate.
    Pharoah P
    BMJ; 1998 Apr; 316(7139):1241-2. PubMed ID: 9553009
    [No Abstract]   [Full Text] [Related]  

  • 32. A need to redefine the consensus on the use of statins in coronary heart disease prevention.
    Fruchart JC
    Eur Heart J; 2000 Oct; 21(19):1572-3. PubMed ID: 10988008
    [No Abstract]   [Full Text] [Related]  

  • 33. Extending the benefit of lipid-regulating therapy to primary prevention.
    Jones PH; Gotto AM
    Am J Cardiol; 1995 Sep; 76(9):118C-121C. PubMed ID: 7572680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secondary prevention of coronary heart disease: the role of fibric acids.
    Haffner SM
    Circulation; 2000 Jul; 102(1):2-4. PubMed ID: 10880405
    [No Abstract]   [Full Text] [Related]  

  • 35. Cholesterol-lowering drugs for primary prevention? The WOSCOP Study.
    Muntoni S
    Pharmacol Res; 1997 Mar; 35(3):169-70. PubMed ID: 9229402
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical and economic considerations of coronary heart disease: a managed care approach. Proceedings based on presentations from two conferences, Cardiovascular Event Reduction: Defining the Role of HMG Therapy in Managed Care, held November 14-16, 1997 in Philadelphia, and Pharmacoeconomics & Outcomes Issues of Lipid Therapy, held November 5-7, 1997 in Orlando.
    Am J Manag Care; 1998 Apr; 4(4 Suppl):S168-233. PubMed ID: 10180343
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model.
    Muls E; Van Ganse E; Closon MC
    Atherosclerosis; 1998 Apr; 137 Suppl():S111-6. PubMed ID: 9694550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What do the statin trials tell us?
    Waters DD
    Am J Manag Care; 2001 May; 7(5 Suppl):S138-43. PubMed ID: 11383375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease--related events.
    Ito MK; Delucca GM; Aldridge MA
    J Cardiovasc Pharmacol Ther; 2001 Apr; 6(2):129-35. PubMed ID: 11509919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.